Consistently, high levels of CD38 have been found in many tumors, indicating therapeutic approaches, such as the use of CD38−/− model mice and CD38 inhibitors to inhibit the progression of glioma [95], lung adenocarcinoma [93] and the outgrowth of primary melanoma [96]. Here, CD38 is linked to central nervous system cancer.